Literature DB >> 11389351

Natural history of choroidal neovascularization in high myopia.

D G Miller1, L J Singerman.   

Abstract

High myopia, or pathologic myopia, usually refers to a condition in which individuals have greater than 6 diopters of myopia or an axial length greater than 26 to 27 mm. The natural history of choroidal neovascularization in high myopia is variable, and reports to date have some conflicting information, but analysis shows fairly poor final visual outcomes. This outcome complicates recommendations for treatment and must be considered in future studies aimed at managing this disease.

Entities:  

Mesh:

Year:  2001        PMID: 11389351     DOI: 10.1097/00055735-200106000-00014

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  15 in total

1.  The role of heredity in determining central retinal thickness.

Authors:  S H Melissa Liew; Clare E Gilbert; Tim D Spector; John Marshall; Christopher J Hammond
Journal:  Br J Ophthalmol       Date:  2007-03-14       Impact factor: 4.638

2.  [Statement from the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration : October 2017].

Authors: 
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

3.  MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial.

Authors:  Alicia Ruiz-Pomeda; Belén Pérez-Sánchez; Isabel Valls; Francisco Luis Prieto-Garrido; Ramón Gutiérrez-Ortega; César Villa-Collar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117

4.  Treatment of myopic choroidal neovascularization with posterior sub-Tenon's bevacizumab injection (Avastin ®).

Authors:  I-Chia Liang; Yu-Ying Chang; Tong-Sheng Lee; Yi-Ru Lin; Kwan-Rong Liu
Journal:  Int Ophthalmol       Date:  2014-02-02       Impact factor: 2.031

5.  Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study.

Authors:  R Hera; C Chiquet; J P Romanet
Journal:  Int Ophthalmol       Date:  2013-03-29       Impact factor: 2.031

6.  Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

Review 7.  Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.

Authors:  Maria-Magdalena Guichard; Géraldine Peters; Cengiz Tuerksever; Christian Pruente; Katja Hatz
Journal:  Ophthalmologica       Date:  2019-08-06       Impact factor: 3.250

9.  BMP-2 Is Involved in Scleral Remodeling in Myopia Development.

Authors:  Honghui Li; Dongmei Cui; Feng Zhao; Lijun Huo; Jianmin Hu; Junwen Zeng
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

Review 10.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.